Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
22 mars 2023 07h30 HE
|
Wave Life Sciences USA, Inc.
Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably engage RNA targets and translate preclinical data to the clinic Extended...
Muscular Dystrophy Association Announces Recipient of 2023 MDA Legacy Award for Achievement in Clinical Research is Merit Cudkowicz, MD, MSC, Renowned Neurologist and Clinical Researcher in ALS
06 mars 2023 09h00 HE
|
Muscular Dystrophy Association
New York, NY, March 06, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Merit Cudkowicz, MD, MSC, a renowned neurologist and clinical researcher in ALS (amyotrophic...
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
06 mars 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., March 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
03 mars 2023 09h00 HE
|
Ractigen Therapeutics
JIANGSU, China, March 03, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RAG-17, a novel siRNA...
Muscular Dystrophy Association Announces Five Recipient Organizations of Advocacy Collaboration Grants
16 févr. 2023 09h00 HE
|
Muscular Dystrophy Association
New York, NY, Feb. 16, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the five organizations receiving $109,065 in grant funding. The grants will promote and...
Muscular Dystrophy Association and Buffalo Bills Running Back Nyheim Hines Launch Nation's Largest St. Patrick’s Day Fundraising Campaign
15 févr. 2023 09h00 HE
|
Muscular Dystrophy Association
New York, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today launched the nation's largest St. Patrick's Day fundraising campaign, MDA Shamrocks. Thousands of...
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
13 févr. 2023 07h00 HE
|
Clene Inc.
MRI results reinforce the clinical neurological improvements previously reportedMRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory effectMRI results...
Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
08 févr. 2023 16h05 HE
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the...
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
07 févr. 2023 07h00 HE
|
AC Immune SA
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 The Michael J. Fox Foundation grant supports the development of AC Immune’s first-in-class TDP-43 PET tracer...
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
31 janv. 2023 07h05 HE
|
uniQure Inc.
~ License of APB-102 further strengthens uniQure’s pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~ ~ APB-102 and uniQure’s c9orf72-ALS...